Company Description
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases.
The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and α7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor.
The company is headquartered in Palo Alto, California.
Country | United States |
Founded | 2016 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 4 |
CEO | Lloyd Jordan |
Contact Details
Address: Building 4, Suite 200 Palo Alto, California 94306 United States | |
Phone | 650 507 0669 |
Website | 180lifesciences.com |
Stock Details
Ticker Symbol | ATNF |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001690080 |
CUSIP Number | 68236V104 |
ISIN Number | US68236V3024 |
Employer ID | 81-3832378 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Lloyd Blair Jordan L.L.B., M.B.A. | Chief Executive Officer and Director |
Sir Marc Feldman Ph.D. | Co-Founder |
Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder and Director |
Prof. Jagdeep Nanchahal M.D., Ph.D. | Co-Founder and Chairman of Clinical Advisory Board |
Eric R. Van Lent | CAO, Principal Accounting and Financial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 1, 2025 | 8-K/A | [Amend] Current report |
Mar 31, 2025 | 10-K | Annual Report |
Feb 25, 2025 | SCHEDULE 13D | Filing |
Feb 25, 2025 | 8-K | Current Report |
Feb 21, 2025 | 8-K | Current Report |
Feb 14, 2025 | SCHEDULE 13G | Filing |
Feb 13, 2025 | SCHEDULE 13G | Filing |
Feb 10, 2025 | 424B3 | Prospectus |
Feb 7, 2025 | EFFECT | Notice of Effectiveness |
Feb 7, 2025 | 8-K | Current Report |